COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

30,741 Articles (22,502 medRxiv, 8,239 bioRxiv)

Most recent first Previous |  Page 1256: Articles 12551-12560  | Next

Durability of SARS-CoV-2-specific T cell responses at 12-months post-infection
Lu, Z., Laing, E. D., Pena-Damata, J., Pohida, K., Tso, M. S., Samuels, E. C., Epsi, N. J., Dorjbal, B., Lake, C., Richard, S. A., Maves, R. C., Lindholm, D. A., Rozman, J., English, C., Huprikar, N., Mende, K., Colombo, R. E., Colombo, C. J., Broder, C. C., Ganesan, A., Lanteri, C. A., Agan, B. K., Tribble, D., Simons, M. P., Dalgard, C. L., Blair, P. W., Chenoweth, J., Pollett, S. D., Snow, A. L., Burgess, T. H., Malloy, A. M.
10.1101/2021.08.11.455984 — Posted: 2021-08-11
Cross-sectional genomic perspective of epidemic waves of SARS-CoV-2: a pan India study
Kumar, S., Bansal, K.
10.1101/2021.08.11.455899 — Posted: 2021-08-11
SARS-CoV-2 Spike S1 glycoprotein is a TLR4 agonist, upregulates ACE2 expression and induces pro-inflammatory M1 macrophage polarisation.
Aboudounya, M. M., Holt, M. R., Heads, R. J.
10.1101/2021.08.11.455921 — Posted: 2021-08-11
Modeling the SARS-CoV-2 mutation based on geographical regions and time
Wei, B., Sun, Y.
10.1101/2021.08.11.455941 — Posted: 2021-08-11
Structural Differences In 3C-like protease (Mpro) From SARS-CoV and SARS-CoV-2: Molecular Insights For Drug Repurposing Against COVID-19 Revealed by Molecular Dynamics Simulations.
Patel, D., Parmar, M., Thumar, R., Patel, B., Athar, M., Jha, P.
10.1101/2021.08.11.455903 — Posted: 2021-08-11
Molecular mimicry between Spike and human thrombopoietin may induce thrombocytopenia in COVID-19
Nunez-Castilla, J., Stebliankin, V., Baral, P., Balbin, C. A., Sobhan, M., Cickovski, T., Mondal, A. M., Narasimhan, G., Chapagain, P., Mathee, K., Siltberg-Liberles, J.
10.1101/2021.08.10.455737 — Posted: 2021-08-11
Multiplexed detection of SARS-CoV-2 genomic and subgenomic RNA using in situ hybridization
Acheampong, K. K., Schaff, D. L., Emert, B. L., Lake, J., Reffsin, S., Shea, E. K., Comar, C. E., Litzky, L. A., Khurram, N. A., Linn, R. L., Feldman, M., Weiss, S. R., Montone, K. T., Cherry, S., Shaffer, S. M.
10.1101/2021.08.11.455959 — Posted: 2021-08-11 Discussion: Onsite
N-dihydrogalactochitosan reduces mortality in a lethal mouse model of SARS-CoV-2
Weiss, C. M., Liu, H., Ball, E. E., Lam, S., Hode, T., Keel, M. K., Levenson, R. M., Coffey, L. L.
10.1101/2021.08.10.455872 — Posted: 2021-08-11
SARS-CoV-2 Spike Affinity and Dynamics Exclude the Strict Requirement of an Intermediate Host
Castelli, M., Scietti, L., Clementi, N., Cavallaro, M., Faravelli, S., Pinnola, A., Criscuolo, E., Diotti, R. A., Clementi, M., Forneris, F., Mancini, N.
10.1101/2021.08.11.455960 — Posted: 2021-08-11
Molecular basis of immune evasion by the delta and kappa SARS-CoV-2 variants
McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L., Dang, H. V., deMarco, A., Franko, N., Tilles, S. W., Logue, J., Miranda, M. C., Ahlrichs, M., Carter, L., Snell, G., Pizzuto, M. S., Chu, H. Y., Van Voorhis, W. C., Corti, D., Veesler, D.
10.1101/2021.08.11.455956 — Posted: 2021-08-11

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).